Akela Pharma, Inc. Announces Board of Director Transition

AUSTIN, TX, July 17, 2012 /CNW Telbec/ - Akela Pharma, Inc. (TSX: AKL) today announced that Mr. Robert W. Rieder is stepping down as Chairman of the Board and as a member of the Board of Directors of Akela Pharma, Inc. to continue his focus as CEO and Director of ESSA Pharma, Inc.

Akela also announced that Mr. Seth E. Lemler, of Lemler Capital Advisors, LLC, has joined Akela's Board of Directors and has been named Chairman of the Board.

Mr. Rieder joined the Board of Akela in May of 2009 and was elected as Chairman of the Board in August 2009.  "Bob has served and dedicated many years as Chairman of the Board of Akela and has overseen the Company through some challenging periods" said Mr. Rudy Emmelot, President & CEO of Akela. "We are very thankful to Bob for his steadfastness and leadership over the past several years and wish him the best of success at ESSA Pharma."

The Company is proud to welcome Mr. Seth Lemler to the Akela Board of Directors as Chairman of the Board. Mr. Lemler currently runs Lemler Capital Advisors and has a distinguished career that has encompassed over 25 years of experience including working for Versa Capital Management, Inc., Morgan Joseph & Co. and Ladenburg Thalmann & Co. Mr. Lemler has advised businesses in industries ranging from health care and manufacturing to technology and consumer products. Mr. Lemler's breadth of experience spans nearly all aspects of operations and finance. "We are proud to have Seth join the Akela Board of Directors and serve as Chairman of the Board" said Mr. Emmelot. "Seth brings tremendous experience and expertise to Akela having advised numerous businesses on strategic planning and execution."

Mr. Lemler holds a Masters of Business Administration from the University of Chicago's Booth Graduate School of Business and is a graduate of the Massachusetts Institute of Technology, where he earned a B.S. degree in Chemical Engineering.

About Akela Pharma, Inc.

Akela Pharma, Inc. is the parent company of PharmaForm, and its common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 32.4 million shares outstanding.

About PharmaForm

PharmaForm, a wholly-owned subsidiary of Akela Pharma, Inc., is a leading specialty contract manufacturer in the area of pharmaceutical dosage form development, specializing in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid filled capsules. Through its diverse offerings, PharmaForm solutions help pharmaceutical and biotechnology clients reach their drug development targets, reduce development costs and accelerate time-to-market for their products.

Akela Pharma Inc.'s common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 32.4 million shares outstanding.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1955. Such forward-looking statements or information may include financial and other projections as well as statements regarding the company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect", anticipate", "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only expectations, and that the company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning our ongoing drug development programs and collaborations as well as the possible receipt of future payments upon achievement of milestones.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that future clinical trial results will be favorable; that our drug candidate will treat target diseases as intended; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, filed on SEDAR at http://www.sedar.com.

All forward-looking statements and information made herein are based on our current expectations as of the date hereof and we disclaim any intention or obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.


For further information:

Akela Pharma, Inc.

Rudy J. Emmelot
Acting President and Chief Executive Officer
Tel: 512-531-6676

Organization Profile


More on this organization


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890